Stephan Harbarth1, Matthew H Samore. 1. Infection Control Program, University of Geneva Hospitals and Medical School, Geneva, Switzerland. stephan.harbarth@hcuge.ch
This Perspective discusses the following new study published in PLoS Medicine:Walker AS, Eyre DW, Wyllie DH, Dingle KE, Harding RM, et al. (2012) Characterisation of Clostridium difficile Hospital Ward–Based Transmission Using Extensive Epidemiological Data and Molecular Typing. PLoS Med 9(2): e1001172. doi:10.1371/journal.pmed.1001172A population-based study in Oxfordshire (UK) hospitals by Sarah Walker and colleagues finds that in an endemic setting with good infection control, ward-based contact cannot account for most new cases of Clostridium difficileinfection.
Clostridium difficile Infection: Difficult to Control?
Clostridium difficile can cause large-scale outbreaks of diarrhea [1],[2]. Significant progress has recently been achieved to improve treatment of symptomatic C. difficile disease [3]. But hospitals affected by C. difficileinfection still face challenges in the effort to control endemic C. difficile infections, which may be related to overuse of antibiotics (e.g., fluoroquinolones, cephalosporins), problems in cleaning services, and poor isolation practices [4],[5]. Furthermore, current diagnostic tests for C. difficile are not sensitive enough [6] and diagnosis can be delayed [7].Evidence for the rate of nosocomial acquisition of C. difficile and the likelihood of within-hospital transmission from patients to patients of C. difficileinfection remains scarce, so an improved evidence base could help improve infection control strategies [8]. Only a few studies have examined in detail the prevalence of C. difficile in hospital patients upon admission and nosocomial transmission rates of C. difficileinfection [9]. For instance, 15 years ago, Samore et al. reported that for most epidemiologically linked contacts of C. difficile cases, positive cultures for C. difficile did not result from transmission from the presumed index case [8]. However, this and other studies were conducted before the emergence of new hypervirulent C. difficile strains and might not reflect the current epidemiology of C. difficile transmission.
Clostridium difficile Infection: Difficult to Transmit?
In a new study published in this issue of PLoS Medicine, Sarah Walker and colleagues examine the epidemiology of C. difficileinfection, focusing on the role of within-hospital transmission among ward patients. The investigators used a simplified model that was populated with observational data from one National Health Service (NHS) Hospital Trust in the United Kingdom, a country that introduced compulsory surveillance with mandatory C. difficile testing of all elderly inpatients with diarrhea in 2008 [10]. Surprisingly, based on the results of their network analysis combined with molecular strain typing, up to three-quarters of patients with C. difficileinfection did not acquire their infecting C. difficile strain during their hospital stay. Using time intervals, strain types, and patient location as plausibility checks, the authors propose that within-hospital transmission accounted for a relatively small number of the overall C. difficile cases detected. However, the rates of transmission varied in different specialty wards, with renal and transplant wards having the highest documented rates. Most of the cases of C. difficile that were attributed to within-hospital transmission occurred shortly after the onset of symptoms of the index case, suggesting that the hospital environment was not, as has previously been claimed, a long-lasting reservoir for this pathogen [7]. Overall, this study suggests that alternative explanations need to be sought for the origin of most of the new onset cases of C. difficileinfection.
Moving On—What Do We Need to Know Next about C. difficile Transmission?
This impressive study addresses an important question—to what extent can we control C. difficileinfection by prevention of transmission from symptomatic C. difficileinfection cases in hospitals? However, there are limitations to the approach chosen in this study, including several possible sources of bias already mentioned by the authors (e.g., selection, misclassification, and information biases).Other potential limitations not considered in this study include the possibility of inter-ward transmission. Patients from different wards might, for instance, be transported to common sectors of the hospital for procedures and diagnostic tests, e.g., X-rays. Potential vectors of transmission, including equipment and health care workers who might care for patients on different wards, could be similarly mobile. In this study, wards were small relative to the hospital size. It is likely that, on average, many more symptomatic C. difficile cases were housed on “other” wards than on the “same” ward. Even though rates of intra-ward transmission per infected case were probably significantly higher than rates of inter-ward transmission per infected case, the absolute number of inter-ward transmissions may have, in fact, exceeded the number of intra-ward transmissions. Second, the poor sensitivity of the Enzyme Immuno-Assay (EIA) testing method for C. difficile diagnosis may have ignored a potentially significant pool of undiagnosed C. difficilepatients (which could have been selected as controls, introducing misclassification bias). Third, antibiotic exposure data were not recorded, which could have biased the dates of onset of symptoms and cross-transmission. Finally, transmission events linked to asymptomatic carriers were not routinely detected [11].
Practical Implications
The two key practical questions related to this study are 1) how much benefit is accrued by blocking transmission from symptomatic C. difficileinfection cases; 2) what proportion of the C. difficile infections that are attributed to within-hospital transmission instead represent already-infected individuals who come into the hospital carrying toxigenic C. difficile strains in their gut flora. The study by Sarah Walker and colleagues cannot provide definitive answers to these questions because it has significant limitations with respect to both issues. The study cannot answer question 1, about benefit accrued by blocking C. difficile transmission, because it did not examine inter-ward transmission. Further, it cannot tell us how many patients came in already colonized or infected because it did not examine asymptomatic C. difficile carriage upon admission and discharge. Attempting to interpret the results of this study with respect to these practical issues highlights the need to utilise models that account for the non-linear dynamics of spread of C. difficile.
Future Studies
Further studies are needed to elucidate answers to the two key questions we have identified above. Investigations should examine the possibility of transmission from falsely EIA-negative symptomatic patients, asymptomatic carriers (patients or health care workers), and community acquisition with importation of C. difficile into the hospital setting [12], and this might require both more data and the use of more advanced transmission models such as hidden Markov models.More detailed screening data, such as a study that reported screening of asymptomatic C. difficile carriers in a large prospective cohort [13], and new models will help to answer the question of whether C. difficile is less of an institutional and more of a community problem than has previously been thought. Proving that the majority of nosocomial C. difficile infections are actually imported into hospitals (with toxigenic C. difficile strains being already present on admission) would be “revolutionary”—however, we believe that the evidence generated by this study, albeit tantalizing, is not yet sufficient to prove this hypothesis.
Authors: Mamoon A Aldeyab; Stephan Harbarth; Nathalie Vernaz; Mary P Kearney; Michael G Scott; Chris Funston; Karen Savage; Denise Kelly; Motasem A Aldiab; James C McElnay Journal: Antimicrob Agents Chemother Date: 2009-03-16 Impact factor: 5.191
Authors: Thomas Haustein; Petra Gastmeier; Alison Holmes; Jean-Christophe Lucet; Richard P Shannon; Didier Pittet; Stephan Harbarth Journal: Lancet Infect Dis Date: 2011-06 Impact factor: 25.071
Authors: Martijn P Bauer; Daan W Notermans; Birgit H B van Benthem; Jon S Brazier; Mark H Wilcox; Maja Rupnik; Dominique L Monnet; Jaap T van Dissel; Ed J Kuijper Journal: Lancet Date: 2011-01-01 Impact factor: 79.321
Authors: Mamoon A Aldeyab; Michael J Devine; Peter Flanagan; Michael Mannion; Avril Craig; Michael G Scott; Stephan Harbarth; Nathalie Vernaz; Elizabeth Davies; Jon S Brazier; Brian Smyth; James C McElnay; Brendan F Gilmore; Geraldine Conlon; Fidelma A Magee; Feras W Darwish Elhajji; Shaunagh Small; Collette Edwards; Chris Funston; Mary P Kearney Journal: Infect Control Hosp Epidemiol Date: 2011-03 Impact factor: 3.254
Authors: Michelle M Riggs; Ajay K Sethi; Trina F Zabarsky; Elizabeth C Eckstein; Robin L P Jump; Curtis J Donskey Journal: Clin Infect Dis Date: 2007-09-04 Impact factor: 9.079
Authors: S B Debast; N Vaessen; A Choudry; E A J Wiegers-Ligtvoet; R J van den Berg; E J Kuijper Journal: Clin Microbiol Infect Date: 2009-03-23 Impact factor: 8.067
Authors: Preeta K Kutty; Christopher W Woods; Arlene C Sena; Stephen R Benoit; Susanna Naggie; Joyce Frederick; Sharon Evans; Jeffery Engel; L Clifford McDonald Journal: Emerg Infect Dis Date: 2010-02 Impact factor: 6.883
Authors: Derrick W Crook; Mark H Wilcox; Tim E A Peto; A Sarah Walker; David W Eyre; Madeleine L Cule; Daniel J Wilson; David Griffiths; Alison Vaughan; Lily O'Connor; Camilla L C Ip; Tanya Golubchik; Elizabeth M Batty; John M Finney; David H Wyllie; Xavier Didelot; Paolo Piazza; Rory Bowden; Kate E Dingle; Rosalind M Harding Journal: N Engl J Med Date: 2013-09-26 Impact factor: 91.245
Authors: Dilip Nathwani; Oliver A Cornely; Anke K Van Engen; Olatunji Odufowora-Sita; Peny Retsa; Isaac A O Odeyemi Journal: J Antimicrob Chemother Date: 2014-08-05 Impact factor: 5.790